Patients who were offered the questionnaire prior to being offered the HIV test were less likely to accept re offered the HIV test first: absolute difference of -8.6% (-illustrates the test acceptance percentage for patients under each default treatment assignment separately for those assigned to early and late questionnaire timing. 
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Patients who were offered the questionnaire prior to being offered the HIV test were less likely to accept -13.3% to -3.9%) illustrates the test acceptance percentage for patients under each default treatment assignment separately for those assigned to early and late questionnaire timing. 
Risk of infection
We conducted sensitivity analyses using two alternate risk measure specifications, below. First we specified risk as a binary indicator of any risk;.second we estimated "Denver HIV Risk Score" as a count of risks, specified as a continuous variable.
Any risk. First, we constructed an indicator variable, anyrisk, equal to 1 if patients reported any of the following:
-sex with more than one men and less than 100% condom use, -sex with more than one women and less than 100% condom use, -men who have sex with more than one man, -use of heroin, cocaine, methamphetamines, -subjective risk of infection ≥2 out of 10, or -sharing needles. Table C presents the results of two multivariable linear probability model regressions of HIV acceptance with the Denver HIV Risk Score as a continuous variable; each coefficient is presented as a percentage with 95% confidence intervals estimated using standard errors clustered at the day-zone level. Column 1 presents a model with treatment assignments, Denver HIV Risk Score, and an indicator for patients who did not complete questionnaire; column 2 adds to that interaction terms between the treatment assignments and the Denver HIV Risk Score. As with the low-, intermediate-, and high-risk groups tested in the manuscript, likelihood of test acceptance increases with increased Denver HIV Risk Score. Treatment effect estimates for the base Denver HIV Risk Score of zero are higher than the average effect in column 1, with statistically significantly smaller opt out effects as risk increases, mirroring the main results reported in Table 2 of the manuscript for those coded at High Risk. The coefficients on active choice and opt out (13.6 and 27.6, respectively) are significant at the p<0.001 level and similar to those found using risk categories and continuous risk score (methods from manuscript and in Appendix Table A, respectively). Each of the components is significant at the P<0.01 level with the exceptions of age 33-46 (5.9, 95% CI 1.05 to 10.7); age 22-25 or 55-60 years and previously tested for HIV were not significantly different than zero. Column 2 presents the same model as column 1, with the addition of interaction terms for each of the risk factors with each of the treatment assignments. IV drug use 7.9*** (2.7 to 13.2) 12.2** (2.9 to 21.5) Active choice x IV drug use -6.2 (-19.8 to 7.4) Opt out x IV drug use -5.4 (-18.0 to 7.3)
Previously tested 2.8 (-0.8 to 6.5) 3.8 (-2.7 to 10.3) Active choice x Previously tested -0.2 (-9.4 to 8.9) Opt out x Previously tested -2.9 (-11.7 to 5.9)
Did not complete questionnaire -13.0*** (-17.8 to -8.3) -13.2*** (-17.9 to -8.4) Constant 22.3 (15.5 to 29.2) 20.4 (9.2 to 31.6) Observations 4,800 4,800 HIV test acceptance is dependent variable. Constant represents the test acceptance percentage under the base case, opt-in testing. Robust standard errors in parentheses. *** p<0.01, ** p<0.05, * p<0.1 "DR" represents Denver HIV Risk Score. DR age 4: age 22-25 or 55-60. DR age 10: age 26-32 or 47-54. DR age 12: age 33-46 Table E presents results from four OLS regressions of acceptance of HIV test on several risk factors and demographics. The Denver HIV Risk Score categories for age are the only Denver HIV Risk Score elements used for these models. Column 1 combines the results of several univariate regressions, each of which is presented as an odds ratio with standard errors clustered at the day-zone level. The Treatment Assignment coefficients are from a model including only dummies for Active Choice and Opt Out; each of the other sets of rows includes these variables plus just that risk factor. Column 2 likewise presents the results of multiple logit regressions of acceptance on each risk factor, with the addition of interaction terms between the treatment assignments and the risk factors (the active choice and opt-out coefficients are omitted here, as they vary with each regression). Columns 3 and 4 present the results of multivariate OLS regressions of HIV acceptance on all of the risk factors entered together in the model; column 4 adds the full set of interaction terms in a single model. 14.4** (0.6 to 28.1) DR age 10 4.5*** (1.5 to 7.5) 6.6** (1.6 to 11.6) 6.3** (1.2 to 11.5) 8.3* (-6.7 to 17.2) Active choice x DR age 10 -2.8 (-10.0 to 4.4) -9.0 (-21.9 to 3.9) Opt out x DR age 10 -4.9 (-11.7 to 1.8) 3.8 (-8.8 to 16.3) DR age 12
1.4 (-1.8 to 4.6) 1.4 (-3.9 to 6.7) 5.7** (0.5 to 10.9) 4.3 (-4.7 to 13.2) Active choice x DR age 12 -2.0 (-9.6 to 5.5) -4.7 (-17.9 to 8.4) Opt out x DR age 12 3.1 (-4.1 to 10.4) 9.3 (-3.6 to 22.2) Male -3.7*** (-6.6 to -0.8) 
